FN2 Earnings Intelligence
MRK revenue earnings history
Merck & Co., Inc. (MRK) quarterly reported and estimated revenue history by fiscal quarter.
Earnings History
Merck & Co., Inc.
The Q2 analysis supports the view that resilient demand and pipeline progress can underpin Merck's growth narrative: revenue increased 5%, full-year revenue guidance was raised, and multiple launches and late-stage milestones advanced. The evidence is not one-directional, with access, regulatory, competitive, and one-time-charge risks still material.
Merck & Co., Inc.
Merck's Q1 2026 results underscore a company in transition: core Keytruda revenue remains strong, but the earnings profile is being reshaped by large one-time charges (Cidara: $9B) and strategic bets (pending Terns acquisition, Google Cloud AI partnership). Revenue beat consensus by roughly $440M, growing 5% YoY on oncology and animal-health strength. Management raised full-year EPS guidance to $5.04-$5.16, reflecting operational confidence. The pipeline showed breadth with FDA approval of IDVYNSO for HIV, priority reviews for I-DXd and WELIREG combinations, and over 20 planned product launches. However, Gardasil's 22% decline on China and Japan weakness and the approaching Keytruda LOE in 2028-2029 remain meaningful headwinds. The market initially reacted negatively (-2.6% abnormal move) but subsequently drifted +8.7% higher, suggesting investors ultimately looked past the one-time…
Merck & Co., Inc.
The supplied analysis supports a measured growth case: launches, pipeline progress, animal-health expansion and acquisitions provide growth avenues, while pricing pressure, generic competition and Keytruda's intellectual-property runway constrain confidence.
Merck & Co., Inc.
The analysis supports a constructive but conditional view: oncology momentum, newer launches, a deep pipeline and OHTUVAYRE broaden Merck's growth platform, while pricing, generic competition and execution risks require monitoring.
Merck & Co., Inc.
The supplied analysis supports a cautiously constructive operating thesis: diversified launches, pipeline progress and portfolio optimization provide growth avenues, but GARDASIL China weakness, tariff exposure, regulatory execution and KEYTRUDA loss-of-exclusivity risk remain material offsets.
Merck & Co., Inc.
The supplied analysis supports a cautiously constructive view of Merck's operating trajectory: oncology, new launches, Animal Health and the late-stage pipeline provide growth support, while maintained guidance is a stabilizing signal. The thesis remains conditional on managing tariffs, Gardasil weakness in China and the longer-term Keytruda loss-of-exclusivity transition.
Merck & Co., Inc.
The supplied analysis supports a constructive but qualified view: Merck's growth is being supported by KEYTRUDA, Animal Health and newer products such as WINREVAIR, while China vaccine weakness, KEYTRUDA exclusivity and pipeline execution create material offsets.
Get the MRK recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.